Recommendations of the Czech Society of Haematology for the diagnosis and treatment of immune thrombocytopenia in adults

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113 (11): 2386–2393.

2. Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J. 2018; 16: 20.

3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339 (22): 1585–1594.

4. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997; 89 (9): 3097–3103.

5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413 (6855): 488–494.

6. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017; 15 (2): 312–322.

7. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996; 87 (10): 4223–4234.

8. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339 (22): 1578–1584.

9. Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017; 4 (4): e157–e164.

10. Upadhyay VA, Geisler BP, Sun L, et al. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. Br J Haematol. 2019; 186 (3): 490–498.

11. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010; 5 (4): e10208.

12. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18 (10): 2496–2502.

13. Takahashi T. Direct antiglobulin test-negative autoimmune hemolytic anemia. Acta Haematol. 2018; 140 (1): 18–19.

14. Vrbensky JR, Moore JE, Arnold DM, Smith JW, Kelton JG, Nazy I. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a dia­gnostic test. J Thromb Haemost. 2019; 17 (5): 787–794.

15. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014; 12 (4): 497–504.

16. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3 (22): 3780–817.

17. Palau J, Sancho E, Herrera M, et al. Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. Hematology. 2017; 22 (8): 484–492.

18. Bradbury CA, Pell J, Hill Q, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New Engl J Med. 2021; 385 (10): 885–895.

19. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 1993; 82 (5): 1415–1421.

20. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3 (23): 3829–3866.

21. Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019; 94 (12): 1314–1324.

22. Grainger JD, Kuhne T, Hippenmeyer J, Cooper N. Romiplostim in children with newly dia­gnosed or persistent primary immune thrombocytopenia. Ann Hematol. 2021; 100 (9): 2143–2154.

23. Cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015; 102 (1): 7–11.

24. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Engl J Med. 2007; 357 (22): 2237–2247.

25. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371 (9610): 395–403.

26. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018; 183 (3): 479–490.

27. Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385 (9978): 1653–1661.

28. Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in dia­gnosis and role of combination treatment. Blood. 2020; 135 (7): 472–490.

29. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93 (7): 921–930.

30. Kappers-Klunne MC, van‘t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001; 114 (1): 121–125.

31. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995; 85 (2): 351–358.

32. Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004; 116 (9): 590–594.

33. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002; 117 (3): 712–715.

34. Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to dia­g­­nosis and treatment. Sem Thromb Hemost. 2020; 46 (3): 275–288.

35. Zoghlami-Rintelen C, Weltermann A, Bittermann C, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol. 2003; 82 (5): 290–294.

36. Mageau A, Terriou L, Ebbo M, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment. Am J Hematol. 2022; 97 (1): 10–17.

37. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005; 90 (6): 829–832.

38. Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016; 3 (10): e489–e496.

39. Kovaleva L, Apte S, Damodar S, et al. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. Immunotherapy. 2016; 8 (12): 1371–1381.

40. Zhou Z, Qiao Z, Li H, et al. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases. Autoimmunity. 2016; 49 (1): 50–57.

41. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. American journal of hematology. 2008; 83 (2): 122–125.

42. Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. New Engl J Med. 2018; 379 (1): 32–43.

43. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011; 117 (5): 1499–1506.

44. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017; 130 (21): 2271–2277.

45. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75 (5): 795–810.

46. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018; 131 (11): 1172–1182.

47. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013; 121 (1): 38–47.

48. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2017; 2017 (1): 144–151.

49. Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current dia­gnostics and therapy: recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018; 41 (Suppl 5): 1–30.